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Eosinophils have numerous functions for defense against pathogens, despite 
being only 1-5% of total circulating blood leukocytes. Most well known for their actions 
contributing to asthma and allergic disease, eosinophils are thought to have homeostatic 
roles in the thymus, uterus, mammary glands, and gut. Furthermore, recent studies have 
also indicated a role for eosinophils as sentinels of tumorigenesis (2-6). Our studies 
show that eosinophils can elicit tumoricidal activity in a dose dependent manner against 
a variety of cancer cells. We also attempted to optimize the cytotoxicity of eosinophils 
by activating different receptors. We were able to verify different methods to stimulate 
eosinophil activation, including incubation with cytokines, especially granulocyte 
macrophage, colony stimulating factor (GM-CSF), and crosslinking the FcαR. 
Eosinophils do have tumoricidal activity, but further research is needed to both 
understand this interaction and to optimize the eosinophil’s tumoricidal properties.  
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CHAPTER I  
INTRODUCTION 
 Eosinophils have a wide repertoire of functions for defense against pathogens, 
despite being only 1-5% of total circulating blood leukocytes. Eosinophil differentiation 
and survival is predominantly regulated by interleukin-5 (IL-5), and eosinophil 
migration is largely in response to the chemokine eotaxin-1. Eosinophils are also 
considered important for the pathogenesis of asthma and allergic diseases. Thus, 
inhibiting eosinophil proliferation and activity by targeting IL-5 and its receptor subunit 
IL-5Rα is a common therapeutic goal for these conditions [1]. 
Interestingly, eosinophils are found in basal levels in the thymus, uterus, 
mammary glands, and gut and are thought to have beneficial tissue homeostasis. 
Furthermore, recent studies have also indicated a role for eosinophils as sentinels of 
tumorigenesis. Firstly, tumor associated eosinophilia has been widely described with an 
improved prognosis in colon, breast, colorectal, nasopharyngeal, oral, gastric, and head 
and neck cancers [2-7]. More recently, murine studies have indicated that eotaxin is 
necessary to clear melanomas and that eotaxin deficient mice have lower tumor 
clearance. Furthermore, IL-5 transgenic mice have decreased tumor metastasis. A 
tumoricidal role for eosinophils against a human colorectal cancer cell line has been 
suggested, in vitro, and was cell contact-dependent and required the adhesion molecule 
CD11a/CD18 [8-10].   
                                                 
 Reprinted with permission from “Therapeutic Strategies for Harnessing Human Eosinophils in Allergic 
Inflammation, Hypereosinophilic Disorders, and Cancer” by Z. J. Amini-Vaughan, 2012. Curr Allergy 
Asthma Resp, 12, 402-412. Copyright [2012] by Springer. 
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We tested the hypothesis that eosinophils have the potential for tumoricidal 
activity against a broad spectrum of tumors, and thus have the potential to be harnessed 
as a novel tumoricidal immunotherapy. We did this in two parts. First, by investigating if 
eosinophils could attenuate tumor cell viability, and second, by investigating the 
mechanism of eosinophil activation and release of cytotoxic molecules in hopes to 
amplify the eosinophil’s tumoricidal effect.  
The Eosinophil 
Eosinophils are innate immune effector cells best known for providing host 
defense against parasites, as well as playing a role in the pathogenesis of allergic 
diseases such as asthma, and in hypereosinophilic syndromes [1,11-13]. In the past 
decade, additional physiologic roles for eosinophils have emerged, which include 
coordination of tissue remodeling events, orchestration of homeostatic functions, and 
regulation of innate and adaptive immunity [1,11-13].  Typically, eosinophils are found 
in low numbers in the blood (1-4% of total peripheral blood leukocytes; less than 500/cu 
mm), and under homeostatic conditions are also found within mucosal tissues, as well as 
primary and secondary lymphoid organs [14]. Eosinophils can be rapidly generated from 
bone marrow progenitors and recruited to sites of inflammation. The cytokine, IL-5, is 
essential for the differentiation and survival of eosinophils from hematopoietic 
progenitors [15]. Eosinophils and their progenitors express the IL-5R which is composed 
of a ligand specific alpha chain (IL-5Rα) and the common beta receptor (βc). The βc 
chain is shared by interleukin-3 receptor (IL-3R) and granulocyte macrophage-colony 
stimulating factor receptor (GM-CSFR) and combines with their respective α chains 
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[16].   Chemotactic molecules are necessary for eosinophil recruitment and migration. 
Eotaxin-1 is an eosinophil specific chemokine and is the most potent chemokine for 
eosinophils [17,18]. Other less selective chemokines include RANTES, eotaxin-2, 
eotaxin-3, monocyte chemoattractant protein (MCP) 2 and MCP-3 which also utilize the 
eotaxin-1 receptor (CCR3) [17,18]. 
Central to eosinophil effector functions is the capacity of these cells to 
immediately release their tissue-destructive cytoplasmic granules upon activation by 
various stimuli.  Eosinophil granule secretion leads to the release of preformed pro-
inflammatory mediators such as cytokines, chemokines, lipid and neuro-mediators, 
reactive oxygen species, growth factors, and cationic proteins [1,11-14].  Eosinophils are 
characterized by the presence of specific granules that contain four classic cationic 
proteins: major basic protein (MBP), eosinophil peroxidase (EPO), eosinophilic cationic 
protein (ECP), and eosinophil-derived neurotoxin (EDN) [1,11-14].  The collective 
destructive power of these cytotoxic proteins provides efficacy against infectious 
organisms, accounts for the bystander damage to host tissue during eosinophilic 
inflammation, and makes them potentially attractive candidates for use as tumoricidals. 
Eosinophils mediate airway remodeling via profibrotic cytokines, such as trandforming 
growth factor beta (TGFβ), and eosinophils are the largest producers of TGFβ in the 
airway [19,20]. TGFβ contributes to airway remodeling by detaching airway epithelial 
cells and increasing deposition of extracellular matrix proteins which causes fibrosis via 
matrix metalloproteinases (MMP) and IL-6 [19,20]. 
 
  4  
  
 
Eosinophils in Host Defense 
Eosinophils are central to host immunity against parasites [21-24]. In addition, 
eosinophils can effectively participate in immunity to bacterial and viral infections via 
ligation of pattern recognition receptors by damage associated molecular pattern 
molecules (DAMPs) and pathogen associated molecular pattern molecules (PAMPs) to 
pattern recognition receptors [22,24]. Eosinophils are most effective against helminth 
parasites. When parasites infiltrate host tissues, a Th2 response is elicited which 
increases the generation of eosinophils under the influence of IL-5 [21,23]. Eosinophils 
are recruited to the site of infection by eotaxin-1. Once in contact with the parasite, the 
eosinophil degranulates to release reactive oxygen species and cytotoxic molecules such 
as EDN, EPO and MBP [23]. Eosinophils will also secrete lipid bodies which contain a 
variety of eicosanoids that are necessary (along with mast cells) for the smooth muscle 
modulation that occurs in peristalsis designed to expel parasites [23]. In contrast, 
eosinophils promote parasite infection by aiding in the establishment of Trichinella 
spiralis, while also limiting parasite load through the prevention of larval spread while 
still acting to eradicate the adult form[25,26]. 
Eosinophils in Allergic Inflammation and Eosinophilic Syndromes 
  Eosinophils have a firmly established role in allergic inflammatory responses. In 
humans and mice, one of the hallmarks of asthma is eosinophilic infiltration of the 
bronchial mucosa and submucosa, and the number of airway eosinophils is directly 
associated with disease severity in asthmatic patients [27,28]. A role for eosinophils in 
the pathogenesis of asthma was experimentally supported using eosinophil-deficient 
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mice, which had markedly diminished allergen-induced airway inflammation and 
markedly diminished bronchial hyper-reactivity [29,30]. Similar results were seen with 
IL-5 deficient mice, implicating the IL-5/eosinophil axis in allergic inflammation [31]. 
This axis was likewise implicated in humans by the presence of increased IL-5 in 
bronchoalveolar lavage fluid and bronchial biopsies of patients with allergic asthma [32-
35].  
Perhaps where eosinophilic pathology is most blatant is in hypereosinophilic 
syndromes (HES), which encompass a variety of disorders whose commonality is 
chronic elevation of blood eosinophil counts [36-38]. HES can cause complications such 
as cardiomyopathy, hepatosplenomegaly, neuropathy, skin lesions, and pulmonary 
disease. These symptoms can be fatal if untreated, and are secondary to the tissue 
damage caused by the eosinophils’ toxic mediators. Subtypes of HES are being 
delineated, and include those with the PGDF-FIPL1 fusion gene, those secondary to 
increased IL-5 production, as well as idiopathic causes [36-38]. 
Other diseases characterized by eosinophilia include eosinophilic esophagitis 
(EE) and eosinophilic gastroenteritis (EG), referring to excess eosinophil infiltration of 
the esophagus and the stomach or intestines, respectively [39-41].  Experimentally, 
eotaxin deficient mice had attenuated EE and IL-5 deficient mice had complete ablation 
of EE [42]. EG can occur in all parts of the gastrointestinal tract, and like EE, is usually 
caused by allergic responses. Churg Strauss disease is also characterized by 
hypereosinophilia, and nasal polyposis is characterized by increased IL-5 production and 
infiltration of eosinophils in the polypoid tissue [43-45]. 
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Duality of Eosinophil Physiology 
The descriptions above demonstrate that eosinophils can be harmful or 
beneficial. There are two prevailing paradigms to explain this duality: either (1) the 
participation of eosinophils in allergic inflammation are part of a common physiologic 
Th2 immune response to environmental insults at the host-environment interface, or (2) 
eosinophils in allergic inflammation are a physiologically unintended or misdirected 
pathologic response that stems from the host’s use of the Th2 anti-parasite immune 
response pathway [46]. In support of the first option, the LIAR hypothesis specifically 
emphasized that the role of eosinophils is to provide “Local Immunity and Remodeling 
Repair,” explaining that the basal levels of eosinophils in the tissues are responsible for 
homeostatic remodeling [46,47]. Hence, the allergic response would be an over 
exuberant, intended response to potentially harmful environmental antigens.  By 
extension, Th2 immune responses may have also specifically evolved against non-
infectious noxious agents or toxins as a mechanism to promote behavioral change (like 
the avoidance venomous stinging or biting animals). Whether Th2 immune responses 
evolved independently against parasites and non-infectious noxious agents, or are based 
on a shared mechanism continues to be debated [46,47].  
IL-5 and the IL-5 Receptor Complex 
Eosinophils are critically dependent on IL-5 for their differentiation, activation, 
prolonged survival, increased adhesion to vascular endothelial cells, and augmentation 
of cytotoxic activity [1,11-13]. IL-5 is a glycoprotein homodimer that is produced by 
Th2 cells, as well as by natural killer (NK) cells, mast cells, basophils and eosinophils 
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[15]. Activated eosinophils produce IL-5 in an autocrine fashion to prolong their 
survival, and some evidence suggests that IL-5 is necessary for eosinophil migration 
along with chemokines like eotaxin-1 and RANTES [48].  
IL-5 binds to a heteromeric receptor composed of a 65kD, high affinity, ligand-
specific IL-5Rα and a homodimeric 130kD βc, which is common to the GM-CSFR and 
the IL-3R [16]. Structurally the IL-5 homodimer is composed of two four alpha helix 
motifs A-D and A’-D’ that are arranged in an up-up-down-down antiparallel 
configuration connected by loops [16,49]. The homodimer conformation interdigitates 
the A, B, and C helices from one molecule and the D’ helix from the other molecule, 
thereby yielding a molecule with a pair of four alpha helical bundle motifs with a C2-
axis of symmetry [50]. Although this structure provides the homodimer with two 
potential binding domains for IL-5Rα and two for βc, only one IL-5Rα has been shown 
to directly bind to IL-5 [50].  The structural interactions of IL-5Rα-bound IL-5 to βc 
have yet to be solved, but are predicted to be limited to one βc. The IL-5 binding domain 
for IL-5Rα lies within the 1st and 3rd antiparallel loops, while the βc binding domain is 
anchored by the glutamate-13 residue (Glu-13) of IL-5 [50,51].  A recent 
crystallography study showed that steric hindrance is responsible for only one IL-5Rα 
being bound by the IL-5 homodimer [52]. It is predicted that IL-5 and the IL-5R 
complex forms in the same way that the GM-CSF and the GM-CSFR forms a dodecamer 
complex, with two IL-5/IL-5Rα complexes binding to one βc, followed by further 
aggregation of these ligand/receptor complexes, which enables engagement of adjacent 
  8  
  
 
βc, thereby facilitating transphosphorylation of JAK2 and signal transduction via STAT5 
(Figure 1) [53].  
The IL-5Rα extracellular region consists of 3 fibronectin type III domains (D1, 
D2, D3). D2 binds IL-5’s M2 region using the D2 β1β2 loop while also binding at the 
hinge site between D2 and D3. It is D1 which is thought to be imperative for IL-5 
binding, and dependent on Ile-161[54]. After IL-5 binds to IL-5Rα via disulfide bonds, a 
conformational change occurs to allow IL-5 interaction with the βc.  Both βc and IL-5Rα 
are constitutively associated with JAK kinases, and are responsible for signal 
transduction [55]. The main signaling pathways involved are the JAK/STAT, 
Ras/MAPK, p38/NFκB, and the phosphoinositide 3-kinase (PI3K) pathways. These 
signaling pathways direct the transcription of various genes involved in eosinophil 




Figure 1. Therapeutic Strategies for Antagonizing the IL-5/IL-5R Axis.  
In an inactivated state, the IL-5 receptor consists of two single IL-R chains (dark orange 
chains) and a c dimer (blue and green chains). Two approaches have been used to 
inhibit IL-5-induced signaling in eosinophils: (1) neutralization of IL-5 by humanized 
mAbs, mepolizumab and reslizumab (left panel); and (2) neutralization of the IL-5 
receptor alpha chain (IL-5R) to block IL-5 binding and mediate ADCC lysis, 
benralizumab (right panel). The first blocks the formation of a signaling competent IL-
5R complex (left panel). The second binds the cell surface IL-5R to prevent IL-5 binding 
altogether. However, this approach also leads to antibody-dependent cellular cytoxicity 
(ADCC) caused by Fc receptor binding on NK cells to the anti-IL-5R mAb on 
eosinophils (right panel) 
*Reproduced with permission from [86]
. 
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Strategies for Antagonizing Eosinophils 
As eosinophils play a contributing role to allergic inflammation, asthma, and 
hypereosinophilic syndromes, eosinophil depletion has been a tantalizing target for 
treatment of these conditions. Since IL-5 is a specific mediator of eosinophil 
differentiation and survival, IL-5 and its receptor have evolved as drug targets. 
Alternative strategies for antagonizing eosinophilic inflammation include targeting 
eotaxin, eosinophil adhesion molecules, or eosinophil signaling pathways. However, the 
greatest success has resided in targeting IL-5 or IL-5Rα. 
Targeting IL-5  
Early on it was determined in murine models that IL-5 neutralizing antibodies 
were effective down regulators of eosinophilic inflammation, with similar favorable 
outcomes as those with IL-5- deficient or IL-5Rα-deficient mice [56]. In developing 
anti-IL-5 neutralizing monoclonal antibodies (mAb), the crucial epitopes are within the 
βc binding domain and the IL-5Rα binding domain. Targeting the βc binding domain on 
IL-5 would still allow IL-5 to bind to IL-5Rα on the surface of eosinophils, but signaling 
could not occur since engagement of the βc would be blocked. Conversely, targeting the 
IL-5Rα binding domain on IL-5 would block IL-5 binding to the eosinophil. Targeting 
either of these IL-5 domains would be predicted to be equally efficacious. Currently 
there are only two IL-5 neutralizing mAb in human use, mepolizumab and reslizumab. 
Both of these mAb have been humanized, bind to epitopes within the IL-5Rα binding 
domain (Table 1), and bind to IL-5 with similar affinity, 4.2pM and 20pM, respectively 
[47-60].  Mepolizumab is an IgG1κ antibody, while Reslizumab is an IgG4κ antibody, 
11 
Table 1. Targeting IL-5 and the IL-5R. 
*Reproduced with permission from [86]
and hence exhibit differences in their Fc biologic activity with IgG4κ hveing  poorer 
binding ffinity [58-60]. Whether their isotype differences will be clinically important is 
not clearly defined. Of note, there are no commercially developed mAb that bind the IL-
5 βc binding domain, although this remains a viable target. 




The initial mepolizumab trial targeted asthma patients. In this study, adult males 
with asthma received a single infusion of mepolizumab, and while peripheral blood 
eosinophil levels were reduced, there was no effect on clinical signs and symptoms 
[60,61]. Subsequent studies selected for patients with eosinophilic asthma and subgroups 
that were insufficiently controlled with corticosteroids. In prednisone- dependent 
asthmatics, an infusion of 750mg mepolizumab was administered once a month for five 
months. Patients receiving the intervention had decreased blood and sputum eosinophils 
and improved asthma control as judged by decreased asthma exacerbations and lower 
requirements for prednisone [62]. In another study in adults with corticosteroid- 
refractory asthma, twelve monthly doses of mepolizumab resulted in fewer 
exacerbations and patients improved their asthma quality of life score [63]. These trials 
also saw a subgroup improvement in patients with nasal polyposis.  In an independent 
study on adults with severe nasal polyposis, patients who received two monthly 
infusions of 750mg mepolizumab had a significant reduction in blood ECP and soluble 
IL-5Rα, and nasal IL-5Rα, IL-6, and IL-1β, which correlated with polyp improvement 
based on total polyp score (TPS) [64]. Mepolizumab was approved by the FDA in 2015 
for use in patients with severe asthma attacks refractory to traditional treatment. 
Mepolizumab, named Nucala, will be given as subcutaneous injections every month in 
conjunction with other asthma medications [65].  
Mepolizumab has been used against a variety of eosinophil-mediated diseases, 
and studies have shown remarkable clearance of blood, lung and bone marrow 
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eosinophils. Among the HES, mepolizumab trials have focused on FIP1L1–PDGFRA 
negative patients, since the FIP1L1–PDGFRA fusion gene promotes eosinophilia 
independent of IL-5 and is treated with the kinase inhibitor imatinib [66]. In patients 
requiring corticosteroid treatment for HES, 750mg of mepolizumab was administered 
intravenously every 4 weeks for 36 weeks. Of the patients who received mepolizumab, 
84% lowered their prednisone dosage to below 10mg/day as compared to 43% of the 
placebo group which achieved this end point. The intervention group also had lower 
blood eosinophil numbers (95% less than 600/μL), and the placebo group had a shorter 
time to treatment failure. Overall, hypereosinophilia was better controlled in the 
intervention group [66]. To determine if mepolizumab was equally effective for the 
lymphocytic and non-lymphocytic subsets of HES patients, 750mg mepolizumab was 
administered every four weeks. This study showed that corticosteroid use could be 
reduced to a similar extent, but blood eosinophil numbers were not as attenuated in 
lymphocytic HES as they were in patients with non-lymphocytic HES [67]. 
When used to treat eosinophilic esophagitis, patients who were dysphagic 
(among other symptoms) received 10mg/kg mepolizumab (up to 750 mg) every 4 weeks 
for 3 total treatments. All patients had improved clinical outcomes related to decreased 
dysphagia, blood eosinophil levels were decreased 6-fold, and three of the four patients 
had decreased esophageal epithelial hyperplasia [68]. In a study that looked more closely 
at the molecular modulations, Straumann demonstrated that the improvement in 
dysphagia was likely due to reduction in tenascin C and TGFβ1 in the esophagus, 
although this study showed only mild clinical improvements [69]. To determine if 
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meoplizumab could be safely and effectively used in children, three monthly infusions of 
0.55, 2.5, or 10 mg/kg mepolizumab were administered [70]. In children that had fewer 
than 20 eosinophils per high power field, there was an improvement in esophageal 
erythema, friability and furrows or vertical lines. 
 Mepolizumab has also been used successfully for patients with Churg Strauss 
disease [71]. In a case report of a 28 year old female, monthly infusions of 750mg 
mepolizumab reduced eosinophils to normal levels resolved the patient’s asthma, and 
improved lung parenchyma by chest radiographs [72]. In a clinical trial of patients with 
Churg Strauss disease and marked eosinophilia, four monthly infusions of 750mg 
mepolizumab resulted in a 64% reduction of corticosteroid use at 12 weeks, and a 61% 
decrease at 24 weeks.  Eosinophilia was also reduced, but upon cessation of the study 
exacerbations recurred [73]. 
 Mepolizumab was unsuccessful in the treatment of atopic dermatitis [73,74]. In 
two studies by Oldhoff, mepolizumab did not improve patient prognosis as judged by 
physician global assessment (PGA), scoring atopic dermatitis SCORAD, and thymus 
and activation-regulated chemokine (TARC) scores and by atopy patch test. In these 
studies blood eosinophilia was reduced, but tissue eosinophilia was not [73,74].  
Reslizumab 
In a reslizumab pilot study, 1mg/kg reslizumab was administered intravenously 
once to patients with severe persistent asthma that was not controlled by corticosteroids 
[75]. Eosinophils were significantly reduced by about 50% after 2 days and slowly 
reestablished to about 18% 30 days after reslizumab intervention [75]. However, the 
  15  
  
 
only noticeable improvement was increased forced expiratory volume (FEV) at the 24 
hour post-treatment time point which was not sustained. In a later study of patients with 
poorly controlled asthma and sputum eosinophilia, the intervention group received 
monthly intravenous infusions of reslizumab. Results indicated that while all patients 
had attenuated eosinophil numbers, only the nasal polyposis subgroup showed increased 
lung performance based on an Asthma Control Questionnaire (ACQ) which indicates 
that reslizumab may be an important therapeutic for certain disease subgroups[76].  
In a limited study for HES, a single infusion of reslizumab (1mg/kg) was administered to 
four adults with HES inadequately controlled by corticosteroids [77]. Three patients had 
significant reduction of eosinophilia, and two also had improved clinical symptoms. 
After cessation of treatment, eosinophil levels rebounded and exacerbations occurred. 
The fourth patient had no reduction in eosinophilia, with self-limited exacerbations [77].  
Reslizumab treatment has also been used for pediatric eosinophilic esophagitis [78]. 
Patients received 1, 2 or 3mg/kg reslizumab infusions monthly for four months. While 
all groups had a reduction of eosinophils, complete clearing of the esophagus did not 
occur and esophagitis improvement did not correlate with eosinophil reduction [78]. 
This study reported minimal adverse outcomes, the most common being cough, 
headache, congestion and respiratory tract infection. Reslizumab is presently in further 
clinical trials for the aforementioned diseases to better elucidate the specificity of 
treatment, along with a clinical trial to evaluate its use in patients with loiasis, in an 
effort to limit host tissue damage associated with the loiasis-induced hypereosinophilia 
[79].  
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Targeting the IL-5 Receptor 
There are two commercial therapeutics that target the IL-5R: benralizumab and 
TPI ASM8 [80-82].  Benralizumab is an IgG1κ mAb specific for IL-5Rα [80,81]. This 
drug has been developed to bind to the first fibronectin domain on IL-5Rα which 
attenuates eosinophil number by competitively inhibiting binding of IL-5 to the IL-5R, 
as well as by antibody-dependent cell-mediated cytotoxicity (ADCC) via FcɣRIIIa 
expressed by NK cells, macrophages and neutrophils (see Figure 1) [54,80,81]. The 
eosinophil lowering capability is effective up to 56 days after administration. 
Benralizumab has been shown to be effective in clinical trials with asthma patients in 
whom it reduced eosinophil numbers in a dose dependent manner, as well as reducing 
ECP levels. Benralizumab is also currently in phase II trials for the treatment of chronic 
obstructive pulmonary disease (COPD) [83].  
TPI ASM8 is an antisense oligonucleotide that targets both the βc and eotaxin-1 
[82].  While βc is an attractive target in that it would potentially inhibit the three Th2 
cytokines, IL-5, IL-3, and GM-CSF, chronic treatment might result in pulmonary-
alveolar proteinosis due to inadequate GM-CSF signaling [84,85]. Likewise, targeting βc 
would also target much broader subpopulations of leukocytes.  
TPI ASM8 has been tested with 4 day and 14 day treatments [82]. These short-
term treatment regimens and the short half-life of TPI ASM8 may mitigate potential 
chronic effects that could arise. In one study, it was determined that the half-life for the 
cocktail was less than 7 hours and that the drug did not accumulate overtime [82]. In 
another study, mild asthmatics were antigen challenged and then inhaled TPI ASM8 
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with increasing doses for 4 days (twice daily for the first three days and then once on the 
fourth day after challenge). After 7 hours there was a 60% reduction in sputum 
eosinophils and a 68% reduction after 24 hours. Likewise, ECP levels were reduced after 
3 days with attenuation of both early and late asthma response [82]. 
Hansen et al. have described an anti- βc mAb that antagonizes signaling in vitro 
[52]. The study showed that their anti-βc mAb inhibited GM-CSF dependent colony 
formation by bone marrow cells from patients with chronic myelomonocytic leukemia, 



















EOSINOPHILS AND TUMOR CELLS 
Cancer therapy is a double-edged sword whose goal is often described as killing 
the tumor before you kill the patient. This is because traditional cancer therapies-
chemotherapy and radiation- target both healthy and compromised cells. Immunotherapy 
has been a burgeoning area of cancer research due to the innate ability of immune cells 
to act as sentinels to both external and internal threats to the body. Along with expanding 
the available anti-cancer drugs and decreasing mortality, by bringing cancer cells to the 
attention of immune cells, the hope is that cancer cells can be specifically targeted, thus 
sparing the healthy cells of the body, which would improve patients’ quality of life. 
Targets of Cancer Immunotherapy 
Cancer is the result in a disturbance of cell cycle regulation. Cancer cells’ 
success depends on numerous factors: the ability to stimulate their own growth, their 
resistance of inhibitory signals and to cell death, the potential to replicate indefinitely, 
angiogenesis, and invasion. Tumor suppressor genes (TSG) respond to aberrant cell 
proteins and thus shut down production of aberrant cells. This is why mutations in 
checkpoint regulating proteins- from tumor suppressor genes, like p53, are common in 
many cancer types [87]. 
Additionally, cancers have a worse prognosis with high endogenous reactive 
oxygen species (ROS) levels and with antioxidants suppression. Yet this tolerance can 
                                                 
  Reprinted with permission from “Therapeutic Strategies for Harnessing Human Eosinophils in Allergic 
Inflammation, Hypereosinophilic Disorders, and Cancer” by Z. J. Amini-Vaughan, 2012. Curr Allergy 
Asthma Resp, 12, 402-412. Copyright [2012] by Springer. 
  19  
  
 
be overcome with excess ROS production, as in radiotherapy. Cancer cells have varying 
tolerance to ROS, and thus varying sensitivities to targets that utilize ROS. Cancer stem 
cells are a subpopulation that have low ROS sensitivity and high antioxidant activity that 
aids in resistance to cancer therapies [88, 89, 90].  
Other checkpoint inhibitors include ipililimab, an anti-cytotoxic T-lymphocyte 
associated protein 4 (CTLA4) mAb, as well as pembrolizumab and nivolumab, anti-
programmed cell death protein 1 (PD1) mAb [91]. CTLA-4 targets a molecule expressed 
by Tregs that has a key role in dampening cytotoxic T cell activation [90]. Ipililimab has 
been approved for treating unresectable or metastatic melanoma. PD1 is involved in 
dampening immune responses and binds to PDL1 and PDL2 which are expressed by 
tumor cells. Both the receptor and ligand were targeted in clinical trials and shown to be 
effective in non-small cell lung cancer (NSCLC) and melanoma. Nivolumab has been 
approved for treatment of unresectable melanoma [93]. 
Vaccines have also been used to treat cancers. For the latter, the most successful 
would be the human papilloma virus (HPV) vaccine, marketed under the name Gardasil. 
As a vaccine, it has no function in treating active cervical cancer but is a measure to 
prevent dysplasia, similar to the hepatitis vaccines. More interesting is the development 
of therapeutic vaccines such as those against prostate cancer and pancreatic cancer that 
have been shown to prolong survival [88,94,95].  
Adoptive cell therapy involves removing the patient’s own cells and enhancing 
them to better target tumor cells before returning them to the patient. Sipuleucel is FDA 
approved and uses dendritic cells to target antigen proastatic acid phosphatase-a specific 
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prostate cancer antigen, similarly T-cell therapies main goal has been to target expansion 
of CD8+ T cells and T cell activation by increasing tumor associated antigen 
immunogenicity [88].   
   Monoclonal antibodies are widely used to treat cancers. Some are cancer specific 
like trastuzumab which targets the HER2/Neu receptor and can only be used against 
HER2/Neu positive breast cancer, while others are more general like bevacizumab 
which inhibits angiogenesis via VEGF inhibition, and is used for multiple types of 
cancer [88, 96]. 
Eosinophils as a Tumoricide 
Although targeting CD8+ cytotoxic T cells and Th1 cytokines has been much 
studied in cancer immunotherapy, tumor associated tissue eosinophilia (TATE) is widely 
recognized and poorly understood. [2-7, 97-100]. The induction of a Th1 immune 
response (by M1 macrophages) is most commonly associated with increased tumor 
control and better prognosis of disease, while the Th2 immune response and its related 
molecules may exacerbate tumor growth and decrease tumor control [101,102]. 
Nonetheless TATE in some cancers has been associated with an improved prognosis [2-
7]. Hence, there is no agreement as to whether or not the presence of eosinophils is 
beneficial or detrimental to patient outcomes.  
As reported by van Driel, TATE has a poor prognosis in cervical cancer, while 
Ishibashi reported that TATE in esophageal squamous cell carcinoma has no correlation 
with prognosis [97,98]. To investigate the potential effect of eosinophils on carcinomas, 
Wong compared the effect of IL-5 neutralizing antibody treatment to placebo on 
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chemically induced squamous cell tumors in hamsters [99]. Eosinophil levels were 
decreased and the tumor burden was lower in anti-IL-5 treated hamsters. Thus, in this 
model, eosinophils appeared to be contributing to tumor pathogenesis. Eosinophils are 
involved in tissue remodeling and they produce VEGF as well as induce endothelial cell 
production of VEGF [103, 104]. Furthermore, eosinophils produce pro-angiogenic 
cytokines: GM-CSF, FGF and TGFα, as well as matrix degrading enzymes in the form 
of MMP, all of which are associated with remodeling [105-108]. Together, this data 
suggest that eosinophils could be used by tumor cells to promote their survival and 
expansion.   
Conversely, patient survival or time to recurrence was improved in patients with 
TATE in some, colon, breast, colorectal, nasopharyngeal, oral, gastric, and head and 
neck cancers [2-7], and metastasis was less frequent in colon cancer and head and neck 
cancer [3,4].  These studies have suggested that eosinophils could be used as a 
prognostic indicator such that patients with TATE could receive less aggressive 
interventions.  
Few studies have been performed to elucidate the connection between 
eosinophils and tumor prognosis. In mice, B16 OVA melanoma tumor clearance was 
dependent on eotaxin and degranulating eosinophils [9]. Additionally, IL-5 transgenic 
(Tg) mice, which overexpress IL-5 and have hypereosinophilia, had decreased tumor 
burden after fibrosarcoma induction, and eotaxin deficient mice had greater 
fibrosarcoma burden. Eosinophil encapsulation of the tumor was prolonged in IL-5Tg 
mice which may account for arrest of tumor growth [109]. Cormier furthers this 
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observation in mice by demonstrating that eosinophil accumulation occurs early in 
subcutaneously injected melanoma tumors and localizes specifically to necrotic tumor 
areas and encapsulated areas [10]. A study performed in vitro on human derived colon 
cancer cells demonstrated that eosinophils can kill tumor cells in a cell contact-
dependent mechanism requiring the adhesion molecules CD11a and CD18, and that key 
molecules involved in the cytotoxic effects were TNF, ECP and Granzyme A [8].  
Materials and Methods 
Cancer Cell Culture 
Human derived cancer cell lines were maintained in culture based on ATTC 
guidelines and in accordance to our IRB guidelines, incubated at 37°C and fed every 48 
hours. Prostate cancer cells, PC3, and erythroleukemic cells, TFI, were grown in 
Roswwll Park Memorial Institute (RPMI) media with 10% fetal bovine serum (FBS).  
NSCLC cells, A549, were grown in Dulbecco’s modified Eagle medium (DMEM) with 
10% FBS, and  RKO, colon cancer cells were grown in Kaighn’s modified Ham’s 
medium (F-12K) with 10% FBS. Cells were treated with trypsin when splitting or 
harvesting cells.  
Eosinophil Isolation and Culture 
 De-identified human blood Leukopaks containing 50-70mL of blood were 
obtained from Gulf Coast Regional Blood Center and diluted 1:5 with HBSS, layered on 
Ficoll-Paque, and centrifuged 700 x g for 30 min at 18˚C. The pellet was harvested and 
red blood cells were lysed and washed away and the remaining granulocytes were loaded 
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into a Robosep with mAb negative selection for eosinophils, using an eosinophil 
purification mAb cocktail (StemCell Technologies). 
 Purity was measured by flow cytometer. Dual staining was performed with CD16 
and CD66b. The eosinophil population is CD66b+ and CD16-, while a double positive 
population would be indicative of neutrophils. Purity was confirmed by light microscopy 
with a Wright-Giemsa stain. Cells of less than 90% eosinophil purity were not used for 
experimentation. Eosinophils were either used directly after isolation or incubated at 
37°F overnight in RPMI media with 10% FBS at a concentration of 1 million cells /mL. 
Unless otherwise noted, cells incubated overnight were also treated with 10ng/mL GM-
CSF and IL-5, while some of the experiments also used other cytokines, discussed 
below. 
Co-culture 
Fresh or overnight incubated eosinophils were cultured with cancer cells at 
varying ratios. Cancer cells were trypsinized, washed, and plated overnight from the 
stock culture at a concentration of 1 million cancer cells per mL media.  Conditions 
varied between experiments and they will be discussed in detail in the results section.  
Measuring Cytotoxicity 
Cytotoxicity was measured by tumor cell death via tumor cell count, and by 
determining viability of tumor cells cultured with and without eosinophils. A cellometer 
was used to count tumor cells and size was used to distinguish tumor cells from 
eosinophils which are easily differentiated by cellometer or flow cytometer. To measure 
viability, flow cytometry analysis was performed after staining with both Annexin V, 
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which is indicative of apoptosis, and propidium iodide (PI), which intercalates into 
nucleic acids and is considered to be a definitive marker of cell death.  
Results 
PC3 Cell Count Reduction Directly Correlates to Eosinophil Concentration  
In our preliminary experiments PC3 cells were co-cultured for 4 hours with 
eosinophils measuring effector:target ratios of 0.1:1 to 20:1. The data showed a 
reduction in tumor cell count that directly correlated to increasing concentrations of 
eosinophils (Figure 2A, 2B). When the data was standardized the dose dependency 
varied between experiments (Figure 2C). For inter-assay standardization we used the 
following formula: 
  # viable tumor cells after co-culture      x 100 
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Figure 2. Eosinophils Decrease PC3 Count in a Concentration-dependent 
Manner. PC3 cancer cells were plated on 12-well plates and incubated overnight. 
Eosinophils were incubated overnight with 10ng/mL IL-5 and GM-CSF then co-
cultured for 4 hrs in the indicated ratios. Viability was assessed via Annexin V and PI. 
The cells were gated based on the pure PC3 (CTL) scatterplot (A) Doses 0.05:1 to 1:1 
(B) Doses 5:1 to 20:1. (C) The percent change in cell count was calculated in each data 
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Eosinophils Have a Broad Tumoricidal Effect  
 In order to investigate the breadth of eosinophil effect on cancer cells, subsequent 
experiments assessed the effect eosinophils had on three more cell lines, A549, RKO, 
and TF1 in addition to the original PC3 cell line. Eosinophils were incubated with tumor 
cells at various effector to target ratios for 4 hours before harvest.  The eosinophil 
population was gated in order to exclude them from analysis, and cancer cell viability 
was determined by dual staining with Annexin V and PI. 
Figure 3 shows the one A549 experiment that was conducted. This showed a 
drastic reduction of A549 viability with the lowest concentration, 5:1::eosinophils:A549, 
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Figure 3. Flowcytometric Analysis of EOS:A549 Co-culture. A549 cancer 
cells were plated on 96-well plates and incubated overnight. Eosinophils were 
incubated overnight with 10ng/mL IL-5 and GM-CSF then co-cultured for 4 hrs 
in the indicated ratios. The eosinophils were gated to exclude them from the 
















The RKO experiments initially showed cytotoxic effects of the eosinophil on  
RKO cells with and initial 11% dead or  dying to 50-80% dead or dying (Figure 4). This 
was also seen when lower concentrations of eosinophils:RKO were added going from 
19% dead or dying to 35% with the lowest concentration, 0.05:1, increasing up to 50% 
with the highest concentration, 20:1 (Figure 4). TF1s did respond to eosinophil treatment 
as well, but with less sensitivity to and in a less linear fashion. The initial experiment 
increased cytotoxicity from 33.7% to 40-50% (Figure 5), while the second experiment 
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Figure 4. Flowcytometric Analysis of EOS:RKO Co-culture. RKO cancer cells were 
plated on 96-well plates and incubated overnight. . Eosinophils were incubated 
overnight with 10ng/mL IL-5 and GM-CSF then co-cultured for 4 hrs at ratios of 5:1, 
10:1 and 20:1. eosinophils were gated to exclude them from the analysis. Viability was 
measured as total positive for Annexin V or PI.  
showed no increase in cytotoxicity from the low concentration treatments. The higher 
doses did have a gradual concentration dependent increasing cytotoxicity from 18% to 
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Figure 4 Continued. RKO cancer cells were plated on 96-well plates and 
incubated overnight. Eosinophils were incubated overnight with 10ng/mL 
IL-5 and GM-CSF then co-cultured for 4 hrs concentrations of 0.05:1 - 
20:1. The eosinophils were gated to exclude them from analysis. Viability 
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Figure 5. Flowcytometric Analysis of EOS:TF1 Co-culture. TF1 cancer cells 
were plated on 96-well plates and incubated overnight. Eosinophils were incubated 
overnight with 10ng/mL IL-5 and GM-CSF then co-cultured with TF1 cells for 4 
hrs at ratios of 5:1, 10:1 and 20:1. The eosinophils were gated to exclude them from 
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Figure 5 Continued. TF1 cancer cells were plated on 96-well plates 
and incubated overnight. Eosinophils were incubated overnight with 
10ng/mL IL-5 and GM-CSF then co-cultured  with TF1 cells for 4 
hrs concentrations of 0.1:1-20:1 as indicated. Eosinophils were gated 
to exclude them from analysis. Viability was measured as total 
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The PC3 cell line was used in three experiments at varying eosinophil:PC3 
concentrations with Figure 6B and 6C duplicates of the same experiment. PC3 cells 
seemed resistant to treatment with cytotoxic effects seen from 73% to 90% in the 5:1 and 
10:1 concentrations, but unsustained in the highest 20:1 concentration at 77% (Figure 
6A). This trend was also seen in the latter experiment with increased cytotoxicity from 
19% to 30-40% but decreased to 26-29% in the 20:1 concentration (Figure 6B and 6C).  
From the aforementioned data, the percent of viable cells was extrapolated for 
comparison between cell lines (Figure 7). There was a cytotoxic effect on all cell lines 
with varying sensitivity with corresponding reduction in viability. A549 cells appeared 
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Figure 6. Flowcytometric Analysis of EOS:PC3 Co-culture. PC3 cells were 
plated on 96-well plates and incubated overnight. Eosinophils were incubated 
overnight with 10ng/mL IL-5 and GM-CSF then co-cultured for 4 hrs 
concentrations of 5:1, 10:1 and 20:1. The cells were gated excluding the eosinophil 
















































Figure 6 Continued. PC3 cells were plated on 96-well plates and 
incubated overnight. Eosinophils were incubated overnight with 
10ng/mL IL-5 and GM-CSF then co-cultured for 4 hrs concentrations 
0.2:1- 20:1 as indicated. Eosinophils were gated to exclude them from 
analysis. Viability was measured as total positive for Annexin V or PI. 





























Tumor associated eosinophilia is an established phenomenon with few studies 
illustrating the mechanism by which eosinophils and tumor cells interact. Our study 
demonstrated that eosinophils are tumoricidal when in co-culture with various human 
derived tumor cell lines. We have also demonstrated that different cancer cell types 
respond with different sensitivities to eosinophils in co-culture. In this paper we touched 
upon targets of cancer immunotherapy, which begs the question, what causes the 
eosinophil to be more effective against one cancer cell line than in another? 
In our experiments, the A549 NSCLC cells were the most sensitive to treatment, 
followed by the other cancer lines, suggesting that eosinophils use pathways that better 
target NSCLC. While mutations in the epidermal growth factor receptor (EGFR) 
garnered much attention and are responsive to EGFR inhibitors like gefitinib and 
erlotinib, only 10% of lung cancer patients are EGFR+,  limiting this treatment.  Lung 
cancer is challenging to treat with traditional therapeutics due to their cancer stem cells 
(CSC) [111]. CSCs boast slow growth kinetics and resistance to ROS destruction due to 
high antioxidant levels. NSCLC becomes responsive therapy with CSC destruction. 
Studies have implicated k-ras and βcatenin as targets to help sensitize the cells to 
therapy with other regulators of stem cell expansion also having potential [112-116]. 
Future eosinophil studies concentrating on ROS targets and CSC may reveal the 
eosinophil’s tumoricidal mechanism. 
A problem we encountered was the inability to reliably separate the eosinophils 
and tumor cells. We initially thought that by gating the cancer cells and eosinophils that 
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there would be distinct populations to measure. However, we found that degranulating 
eosinophils and dying cancer cells could have overlap on the scatterplot. We attempted 
to treat this conservatively by gating and then excluding the eosinophil population, 
though this may have excluded some of our dead or dying cancer cells, hence 
underestimating the effect of the eosinophil treatment. Likewise, at high 
eosinophil:tumor cell concentrations, the degranulating eosinophils could have falsely 
elevated levels of Annexin V, overestimating the appearance of dead or dying tumor 
cells. Other modalities that could have been used include radiolabelling cancer cells and 
measuring the release of radioactive cell contents, excluding eosinophils by surface 
markers (CD16-CD66b+) and by downstream markers such as mitochondrial membrane 

















Given that TATE is well described in cancer patients, and can be associated with 
improved prognosis, the promotion of eosinophil effector function is a potentially viable 
strategy against tumors. To investigate the potential to enhance eosinophil tumoricidal 
activity, we compared tumoricidal activity of eosinophils cultured without or with 
known eosinophil agonists. Since the degranulation of eosinophils is key for eosinophil 
effector function, any strategy that would induce degranulation may be useful. The 
chemokine eotaxin can stimulate eosinophil degranulation, so eotaxin promotion might 
be beneficial. Indeed, an eosinophilotactic molecule was reportedly produced from a 
large-cell anaplastic carcinoma of the lung, so it may be possible to illicit a chemokine 
dependent response via modulation of the tumor [117]. Likewise, many cytokines are 
associated with eosinophil degranulation, including IL-5, IL-33, and GM-CSF [118, 
119].  
Measuring Eosinophil Activation 
 Eosinophil activation can be determined by measuring eosinophil degranulation 
reflected by protein expression in the plasma membrane and release of cytotoxic 
molecules. CD63, is a tetraspanin protein that is a component of the eosinophil 
crystalloid granule, has been shown to translocate to the plasma membrane due to 
eosinophil stimulation. Translocation has been induced by IL-5, GM-CSF, and IL-3 
[120, 121]. 
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 CD69 is found in many hematopoietic cell lines and is upregulated by IL-3 in 
basophils [117, 122, 123]. It is a transmembrane protein with a C-lectin domain, which 
binds to extracellular matrix proteins to affect downstream signaling. CD69 is also 
expressed in eosinophils and has been used as an indicator of eosinophil activation. 
Downstream signaling is regulated by Jak3, STAT5, so STAT5pY could be used to 
measure eosinophil activation along with CD69 translocation to the plasma membrane. 
Enhancing Eosinophil Activation 
Studies have shown that IL-5 and GMCSF can induce eosinophil degranulation, 
so these maintenance cytokines may contribute to an eosinophil’s cytotoxicity against 
tumor cells [125].  Both are necessary for hematopoietic stem cell differentiation into 
eosinophils. GMCSF is secreted by a number of different cell types including 
macrophages, mast cells, and endothelial cells, while also being necessary for directing 
neutrophil differentiation. IL-5 is secreted by Th2 and mast cells to stimulate eosinophil 
maturation and activation and is also secreted in an autocrine manner.  
IL-33 has also been shown to mediate eosinophil adhesion and survival as well as 
degranulation [123,118]. It is expressed by epithelial cells, fibroblasts, and smooth 
muscle cells and mediates a Th2 response via the ST2 receptor.  
Another strategy would be to cross link the surface receptors using an antibody 
specific to the receptor [126]. The eosinophil plays a role in antibody dependent 
immunology largely mediated through the immunoglobin receptors Fc𝛾R, FcαR, and 
FcεR, which are the IgG, IgA, and IgE Fc receptors respectively [127, 1268]. The use of 
protein A or G along with receptor specific antibodies could be used to crosslink 
40 
eosinophil cell surface receptors to initiate signaling cascades that promote 
degranulation. Interestingly, CD89, the FcαR, must be bound by polymeric IgA in order 
to initiate the signaling cascade. When an IgA polymer binds, it leads to inhibition of the 
signaling cascade by partially phosphorylating the ITAMs and downstream molecules 
whereas full phosphorylation activates eosinophils (Figure 8). In order to activate FcαR 







Another target is cell contact adhesion molecules that have been shown to play a 
role in eosinophil degranulation. As previously mentioned, CD11a and CD18 were 
Figure 8. Regulation of Immune Response by FcαR*. (A) ITAM-induced 
activation. Cross-linking of FcαRI by immune complex results in full 
phosphorylation of ITAM tyrosines this leads to the phosphorylation of additional 
signaling adaptors which recruit several downstream molecules. Overall this induces 
immune cell activation with cell responses such as phagocytosis, cytokine synthesis, 
proliferation and degranulation. (B) ITAMi-homeostatic control. Monomeric IgA 
binding to FcαRI results in partial phosphorylation of ITAM tyrosines resulting in 
SHP-1 recruitment. This would in time allow the long-lasting dephosphorylation of 
other signaling pathways. 
*Reproduced from [110]
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shown to be involved in eosinophil tumorcidal activity, as antibodies against these 
molecules attenuated the tumorcidal effect [10]. To investigate the role of cell contact in 
eosinophil activation, we followed Kita’s protocol-coating culture plates with 
extracellular matrix proteins and blocking with human serum albumin before eosinophil 
incubation [129]. Besides those mentioned, other receptors targeted in prior studies 
include pattern recognition receptors, leukotriene receptors, and chemoattractant 
receptors [1, 18, 131]. 
Materials and Methods  
 Eosinophil Isolation and Culture 
 De-identified human blood Leukopaks containing 50-70mL of blood were 
obtained from Gulf Coast Regional Blood Center and diluted 1:5 with HBSS, layered on 
Ficoll-Paque, and centrifuged 700 x g for 30 min at 18˚C. The pellet was harvested and 
red blood cells were lysed and washed away and the remaining granulocytes were loaded 
into a Robosep with mAb negative selection for eosinophils, using an eosinophil 
purification mAb cocktail (StemCell Technologies). 
 Purity was measured by flow cytometer. Dual staining was performed with CD16 
and CD66b. The eosinophil population is CD66b+ and CD16-, while a double positive 
population would be indicative of neutrophils. Purity was confirmed by light microscopy 
with a Wright-Giemsa stain. Cells of less than 90% eosinophil purity were not used for 
experimentation. Eosinophils were either used directly after isolation or incubated at 
37°F overnight in RPMI media with 10% FBS at a concentration of 1 million cells /mL. 
Unless otherwise noted, cells incubated overnight were also treated with 10ng/mL GM-
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CSF and IL-5, while some of the experiments also used other cytokines, discussed 
below. 
Measuring Eosinophil Activation 
 We used FITC CD69 (BDPharmigen) and PE CD63 (Biolegend) as measures of 
eosinophil activation and degranulation. Isotype controls FITC mouse IgG1k and PE 
mouse IgG1k respectively.  
Results 
Effect of Cytokines on Eosinophil Activation and Receptor Expression   
Baseline expression of  IL-3Rα, IL-5Rα, GM-CSFRα and βC was measured to be 
able to compare in later experiments should our treatments affect receptor expression.  
Eosinophils were isolated and flow cytometry was used to measure presence of the 
receptors.  There was no baseline expression of IL-3Rα while there was a basal 
expression of IL-5Rα, the βC chain, CD89-the IgA receptor, and ST2-the IL-33 receptor 
(Figure 9). Cells were then incubated overnight with media or one of the following 
cytokines: IL-3, IL-5, IL-33, or GM-CSF (Figure 10). IL-5Rα and the common beta C 
chains were increased with all treatments while IL-3Rα, and GM-CSFRα had no 
increased expression following any of the cytokine experiments. 
This experiment also measured the effect of cytokine incubation and eosinophil 
activation (Figure 11). We saw that CD69 expression was not increased with overnight 
incubation while CD63 expression was increased with treatment of IL-3 and GM-CSF 
with a smaller activating effect from IL-5 and IL-33. 
 

























Figure 9. Baseline Receptor Expression. Freshly isolated eosinophils were 
incubated with antibodies to the indicated receptors. Receptor expression was 
measured via flow cytometry. 
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Figure 10. Cytokine Treatment and Eosinophil Receptors. Eosinophils were plated 
in 24 well plates and incubated overnight with 10ng/mL IL-5, IL-3, IL-33 or GM-CSF.  
Expression of (A) IL-3Rα, (B) IL-5Rα, (C) GM-CSFRα and (D) βc were measured via 
flow cytometry. 
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IL-33 Increases CD63 Expression 
Similarly, acute incubation of eosinophils with IL-33 induces CD63 expression. 
Eosinophils were freshly isolated as previously described and treated with 5ng/mL IL-5 
and GM-CSF overnight. The eosinophils were treated with IL-33 for 3.5 hours before 
harvest and eosinophil degranulation was measured by CD63 expression. Eosinophils 
had 10% more CD63 positivity when treated with IL-33 compared to control (Figure 
12). 
Figure 11. Cytokine Treatment and Eosinophil Activation. Eosinophils were 
plated in 24 well plates and incubated overnight with 10ng/mL IL-5, IL-3, IL-33 or 
GM-CSF. CD63 (A) and CD69 (B) were measured by flow cytometry. 


















IL-5 and GM-CSF Increase CD63 Expression  
We also measured cytokine eosinophil activation in the presence of anti-
CD89mAb to see if that would enhance the effect. Eosinophils were freshly isolated as 
previously described and treated with media, IL-5 or GM-CSF overnight. The 
eosinophils were treated with anti-CD89mAb 1 hour before harvest and eosinophil 
degranulation was measured by CD63 expression. Eosinophils had greater activation in 
response to GM- CSF than when treated with IL-5. When treated with both IL-5 and 
GM-CSF there was activation greater than IL-5 alone, but less than GM-CSF alone 
Figure 12. IL-33 Increases CD63 Expression. Eosinophils were freshly isolated and 
plated in 96-well plates and then treated with IL-5 and GM-CSF overnight and then 
with media (CTL) or IL-33 for 3.5hrs. CD63 expression was analyzed via flow 
cytometry. 
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(Figure 13), indicating that IL-5 prevents degranulation of eosinophils attenuating the 
effect of GM-CSF. 
Figure 13. IL-5 and GM-CSF Increase CD63 Expression. Eosinophils were 
freshly isolated and plated in 24-well plates and then treated with media control or 
respe ctive cytokines. The next morning they were treated with 100ng/mL anti-
CD89 mAb for 1 hour and CD63 expression was analyzed via flow cytometry.  
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Effect of Cytokines and anti-CD89mAb on Eosinophil Receptors 
Eosinophils were incubated overnight with 10ng/mL IL-5, Il-3, IL-33 or GM-
CSF, and then incubated for 1 hour with 100ng/mL anti-CD89mAb. Flow cytometry was 
used to measure expression of IL-3Rα, IL-5Rα, GM-CSFRα and βC. IL-3Rα and 
GMCSFRα did not have increased expression on any of the treatment groups, while IL-
5Rα, βc-R and were expressed equally on all treatment groups (Figure 14). Eosinophil  
activation was measured using CD69 and CD63 via flow cytometry (Figure 15). CD69 
expression was unchanged, while CD63 expression was increased in all cytokine and 
cross-linked cells, with the highest expression in those treated with IL-3, GM-CSF, and 
IL-5 respectively. 
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Figure 14. Cytokine Treatment, CD89 and Eosinophil Receptors. Eosinophils 
were plated in 24 well plates and incubated overnight with 10ng/mL IL-5, IL-3,  
IL-33 or GM-CSF. And then treated with anti-CD89mAb. Expression of (A) 
IL-3Rα, (B) IL-5Rα, (C) GM-CSFRα and (D) βc were measured via flow 
cytometry.  
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Figure 15. Cytokine Treatment, CD89 and Eosinophil Activation. Eosinophils 
were plated in 24 well plates and incubated overnight with 10ng/mL IL-5, IL-3, 
IL-33 or GM-CSF, then incubated for 1hr with anti-CD89mAb. CD63 (A) and 
CD69 (B) were measured by flow cytometry. 
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CD63 Expression Is Increased with anti-CD89mAb 
Fresh eosinophils were isolated and incubated with 10ng/mL anti-CD89mAb for 
30 min or incubated overnight with 5ng/mL IL-5 and GM-CSF and the next morning 
treated with anti-CD89mAb for 30 minutes (Figure 16A). Activation was measured via 
CD63 expression on flow cytometry. CD63 expression increased when freshly isolated 
eosinophils were treated with anti-CD89mAb. Eosinophils treated overnight had no 
increase in activation as measured by CD63 expression (Figure 16B). 
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Figure 16. CD63 Expression Is Increased with anti-CD89mAb. Eosinophils were 
isolated and incubated with 10ng/mL anti-CD89mAb then stained for CD63 on flow 
cytom etry. (A) Fresh eosinophils were treated for 30 minutes. (B) Eosinophils were 
incubated overnight with 5ng/mL IL-5 and GM-CSF and treated with anti-CD89mAb 
30 mi nutes before harvest. 
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Anti-IgGmAb Increased CD63 Expression  
 Eosinophils were isolated and incubated overnight before treatment with IL-33, 
then with anti-CD89mAb, followed by incubation with anti-IgGmAb. In contrast to 
previous experiments, IL-33 treatment alone has a small effect on eosinophil 
degranulation, while anti-CD89mAb has no effect on CD63 expression. Together, those 
eosinophils treated with IL-33, anti-CD89mAb and anti-IgG1mAb did increase CD63 
















Figure 17. Anti-IgGmAb Increases CD63 Expression. Eosinophils were 
incubated overnight with 10ng/mL IL-5 and GM-CSF. Then 1 hour treatment of 
IL-33, 1 hours treatment anti-CD89mAb, and 1 hour treatment anti-IgGmAb. 
CD63 expression was measured via flow cytometry. Isotype controls were used 
and found to be comparable to the eosinophil control.  
 




 The main goal of this set of experiments was to use known activators of 
eosinophil degranulation to enhance degranulation and to target those that could affect 
tumor survival. Our experiments concentrated on reproducing these experiments to 
harness them in co-culture with tumor cell lines. We demonstrated that overnight 
treatments of IL-5, GM-CSF, IL-33. IL-33 activated eosinophils and this was confirmed 
with an acute incubation. Likewise, we showed that IL-5 and GM-CSF, in the presence 
of anti-CD89mAb, induced CD63 expression. Of note, there was a greater expression of 
CD63 in the GMCSF population with a 74% positivity in contrast to the 22% positivity. 
We also saw that there was not a synergistic effect of the two cytokines together with 
33% CD63 positivity when treated with both IL-5 and GM-CSF. This indicates that IL-5 
dampens degranulation. It is likely that IL-5 acted to stabilize the eosinophil against 
degranulation, acting as a pro-survival cytokine in this instance.  
We were able to utilize principles of previous studies to show that eosinophils 
could be activated by crosslinking the CD89 receptor with anti-CD89mAb as well as 
with anti-IgGmAb. Unexpectedly, incubating the two together did not amplify CD63 
expression, and when we treated with IL-33 we did not see the shift in CD63 that we had 
previously seen.  
As we used donor human eosinophils, the environments they were previously in 
could affect their molecular milieu giving a heterogeneous eosinophil population. It is 
difficult to interpret the data accurately, so repeat studies would best measure the 
internal validity of these experiments.  
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Alternative ways to measure eosinophil activation include downstream indicators 
of activation such as phosphorylated signaling molecules, RNA transcription and protein 
production. Granule contents like EDN, ECP, ROS and MBP could be measured by 
ELISA.   
Not shown here are two experiments we were unable to analyze. The first was to 
create an IgA immune complex consisting of anti-CD89 and Protein G. We did not 
account for the size of Protein G, and our flow cytometer could not process the results. 
In another experiment we used collagen to reproduce a cell-contact mediated eosinophil 
activation. Our control sample did not process appropriately, so we were unable to 













CONCLUSIONS AND FUTURE DIRECTIONS 
The potential to harness eosinophils against cancers is an exciting frontier that 
could potentially lead to technological breakthroughs in clinical medicine. Our studies 
showed that when co-cultured, human eosinophils are tumoricidal to human-derived 
cancer cell lines. One oversight was that we did not provide a negative control 
demonstrating the specificity of eosinophil cytotoxicity to tumor cells. We will repeat 
our experiments use a non-transformable, terminally differentiated cell line to address 
this lapse. Once we show eosinophils’ cytotoxicity to tumor cells we will conduct more 
studies to fully explore the modalities to harness eosinophil cytotoxicity in order to 
optimize effector to target cell ratios. We plan to continue our co-culture experiments 
and remove factors to hone in on the mechanism involved. For cell contact, we propose 
using plates with basket inserts to see if tumor death occurs in the absence of cell 
contact. To look at the various cytokines we could treat the eosinophils with various 
combinations of cytokines and neutralizing antibodies before co-culture to see how the 
cancer cells are affected along with better looking at eosinophil activation and culture 
with and without cytokines. We could also neutralize eosinophil granule contents. ROS 
are an attractive target as they have known implications for tumor survival, so we plan to 
use them as a measure of cytotoxicity along with Annexin V and PI to measure viability. 
We also plan to inhibit ROS production via glutathione to strengthen the link. The role 
of eosinophilia in tumor progression is still unknown, but future studies may provide us 
the insight to harness eosinophils as a cancer immunotherapy. 
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